Aeovian
aeovian.com
Actively hiring
Biologics & Biosimilars
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$37M
1 round on record
Latest round
$37M
Venture round · Oct 2019 · 6 yr ago
Team
51-200
employees, estimated range
Backers
3
FJ Labs, Sofinnova Investments
The money's age
Long since its last round
83 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 12, 2019
Raised a round Venture round $37M · Chemical & Engineering News
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2019 | $37M | — | Chemical & Engineering News |
Backed byfrom the funds' portfolios and accelerator catalogs
FJ Labs 
Sofinnova Investments 
venBio Partners Overview
Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
News
Aeovian Pharmaceuticals: $55 Million Series B Raised To Advance AV078 For Tuberous Sclerosis Complex-Related Refractory Epilepsy
Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company based in Berkeley, California, has closed an oversubscribed $55 million Series B financing to support completion of a Phase 2 proof-of-concept study for its lead candidate, AV078, in tube
Read more
Report
TSC Alliance Endowment Fund Invests in Aeovian Pharmaceuticals to Advance Development of an mTORC1 Selective Inhibitor for Tuberous Sclerosis Complex
The TSC Alliance Endowment Fund, a supporting organization of the TSC Alliance, has invested in Aeovian Pharmaceuticals as part of their Series B financing in support of their Phase 2 trial of AV078, a first-in-class CNS-penetrant selective mTORC1 inhibit
Read more
Report
Aeovian Pharmaceuticals: $50 Million Raised To Develop Selective Therapeutics For Restoring Cellular Metabolic Quality Control
Aeovian Pharmaceuticals - a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway - announced that it dosed the first cohort of participants in a Phase 1 clinical trial for its
Read more
Report
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
/PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit...
Read more
Report
Aeovian Pharmaceuticals patents CD38 inhibitors
Aeovian Pharmaceuticals Inc. has disclosed new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegenerative diseases.
Read more
Report
Aeovian raises $37 million for mTORC1 inhibitors
Chemical & Engineering News (C&EN): Keeping you up to date with the chemistry news that matters most. Published by the American Chemical Society.
Read more
Report
Evotec AG: Evotec Reaches Milestone In Integrated Drug Discovery And Development Partnership With Aeovian
PARTNERSHIP ACHIEVES FAST-TRACK PROGRESS FROM LEAD OPTIMISATION TO NOMINATION OF A PRE-CLINICAL DEVELOPMENT CANDIDATE ("PDC") IN 18 MONTHS EVOTEC RECEIVES UNDISCLOSED PAYMENT AND HAS SECURED AN EQUITY
Read more
Report
Financials
Total raised
$37M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2019 | $37M | Details |